Streetwise Live! Presents Algernon Pharmaceuticals on 01/27/2022. Learn More

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Possible Treatment for CRC Shows Promise

Research Report
  ()
New trial results of Exelixis' cabozantinib in colorectal cancer are encouraging for further development of the biopharma's XL902 in the indication, noted an H.C. Wainwright & Co. report.

‘Strong Data’ Expected From Todos Medical Data Lock

Contributed Opinion
  ()
Todos Medical is set to take on the dominant players in oral antivirals for mild to moderate COVID-19, Pfizer Inc. and Merck & Co. Inc., with "strong data" expected to be released soon for its drug Tollovir.

Fourth COVID-19 Vaccine Shot Shown Less Effective

Research Report
  ()
BioNTech aims to develop a COVID-19 vaccine targeting the Omicron variant, noted an H.C. Wainwright & Co. report.

FDA Gives Fast Track Status to Firm for Adrenal Rescue Pen

Research Report
  ()
Now with fast track status and positive Phase 1 study results, Antares Pharma plans to advance its ATRS-1902 product candidate into a second trial in Q2/22, noted a Ladenburg Thalmann report.

First NSCLC Patient Dosed With Trial Therapeutic

Research Report
  ()
Two recent Vaccitech events, the MAGE trial initial dosing and the acquisition of Avidea's SNAPvax technology, bode well for its ChAdOx1-MVA platform, noted an H.C. Wainwright & Co. report.

Fund Triples Holding of Drug Repurposing Firm

  ()
Several events slated to happen this year could boost Algernon Pharmaceuticals' share price, noted an AlphaNorth Partners Fund performance report.

Derm Biopharma Named Top Growth Pick For 2022

Research Report
  ()
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.

This Pharmaceutical Company Has a Brilliant Concept

Contributed Opinion
  ()
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. Catalysts abound with this genius repurposing company.

Ph1 Trial Results of Dementia Drug Positive

Research Report
  ()
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.

Biotech Co. Partners With Life Sciences Firms

Research Report
  ()
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.

Enrollment Done for COVID-19 Drug Trial

Research Report
  ()
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.

2022 to Be Catalyst Rich for Biopharma

Research Report
  ()
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.

Co.'s samRNA Vaccines Protect Better Against COVID Variants

Research Report
  ()
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.

AI Driven Drug Firm Partners With Merck

  ()
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.

Co. Partners to Test New Cancer Vaccines

Research Report
  ()
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.

Co. Plans to Make 100M Rapid COVID Tests Monthly

Research Report
  ()
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.

New Muscular Dystrophy Drug Shows Promise

  ()
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.

Chen Lin's Top 6 Investment Ideas

  ()
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.

Lead Cancer Drug Gets Fast Tracked

  ()
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.

Analyst: Drug a 'Hidden Gem for 2022'

Research Report
  ()
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish."

Co. Still Compelling After Drug Trial Failure

Research Report
  ()
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report.

Co. Looks To US For Help Fighting Strokes

  ()
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.

Showing Results: 1 to 25 of 119 Next

Get Our Streetwise Reports Resources Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts

"I used the mill commissioning delay to add some positions in MAG."
– Chen Lin, What Is Chen Buying? What Is Chen Selling?
"This is a great buy spot for LIO."
– Clive Maund, CliveMaund.com